Answers are grounded in this paper and cite their sources.
Objective Data on amnioinfusion during trial of labor after cesarean (TOLAC) are limited. We evaluated whether intrapartum amnioinfusion increases the risk of uterine rupture among individuals undergoing TOLAC. Study Design: Retrospective cohort of individuals undergoing TOLAC at a tertiary center (January 2013–June 2025). Per departmental protocol, amnioinfusion was used for repetitive variable decelerations. Individuals with major fetal anomalies, stillbirth, or multiple gestations were excluded. The primary outcome was uterine rupture. Secondary outcomes included unplanned cesarean delivery, postpartum hemorrhage, transfusion, hysterectomy, infectious morbidity, ICU admission, and adverse neonatal outcomes. Multivariable regression was used to estimate adjusted associations. Results Of 131,489 deliveries, 5,303 (4%) met inclusion criteria, of whom 315 (6.2%) underwent amnioinfusion. Individuals receiving amnioinfusion delivered at a later gestational age and had higher rates of labor induction, intrapartum fever, and meconium-stained amniotic fluid. The overall uterine rupture rate was 1%. After adjustment, uterine rupture rates did not differ between the amnioinfusion and control groups (1.2% vs. 1%; adjusted OR 1.2, 95% CI 0.4–3.3; p = 0.7). Amnioinfusion was associated with a higher rate of cesarean delivery (adjusted OR 3.1, 95% CI 2.5–4.0; p < 0.01). Conclusion Among individuals undergoing TOLAC, amnioinfusion was not associated with an increased risk of uterine rupture. These findings provide reassurance regarding its use during TOLAC; however, given the limited number of uterine rupture events, larger studies are needed to confirm its safety.
No takes yet. Share an insight, caveat, or question.
Zloto et al. (2026) studied this question.
Synapse has enriched 6 closely related papers on similar clinical questions. Consider them for comparative context: